The central role of dendritic cells and interferon-α in SLE

Current Opinion in Rheumatology

Volumn 15, Issue 5, 2003, Pages 548-556

  Pascual, Virginia ^a,b   Banchereau, Jacques ^a   Palucka, A Karolina ^a  

^a BAYLOR INSTITUTE FOR IMMUNOLOGY RESEARCH   (United States)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

Dendritic cells; Gene microarrays; Interferon ; Lupus; Plasma cells

Indexed keywords

ALPHA INTERFERON; CD14 ANTIGEN;

DENDRITIC CELL; DNA MICROARRAY; HUMAN; IMMUNOPATHOGENESIS; INTERFERON PRODUCTION; LEUKOCYTE ACTIVATION; PLASMA CELL; PRIORITY JOURNAL; REVIEW; SYSTEMIC LUPUS ERYTHEMATOSUS;

DENDRITIC CELLS; GENE EXPRESSION; HUMANS; INTERFERON-ALPHA; LUPUS ERYTHEMATOSUS, SYSTEMIC;

EID: 0042329609     PISSN: 10408711     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002281-200309000-00005     Document Type: Review

References (79)

1. Lahita RG: Systemic Lupus Erythematosus, edn 3. Academic Press, San Diego, CA; 1999.
2. Mills JA: Systemic lupus erythematosus [see comments]. N Engl J Med 1994, 330:1871-1879.
3. Hahn BH: Antibodies to DNA. N Engl J Med 1998, 338:1359-1368.
4. Shlomchik MJ, Craft JE, Mamula MJ: From T to B and back again: positive feedback in systemic autoimmune disease. Nat Rev Immunol 2001, 1:147-153.
5. Steinman RM: The dendritic cell system and its role in immunogenicity. Annu Rev Immunol 1991, 9:271-296.
6. Steinman RM, Turley S, Mellman I, et al.: The induction of tolerance by dendritic cells that have captured apoptotic cells. J Exp Med 2000, 191:411-416.
7. Steinman RM, Nussenzweig MC: Inaugural article: avoiding horror autotoxicus: the importance of dendritic cells in peripheral T cell tolerance. Proc Natl Acad Sci U S A 2002, 99:351-358. This article discusses the concept of immature DCs as gatekeepers of peripheral tolerance.
8. Janeway CA Jr, Medzhitov R: Innate immune recognition. Annu Rev Immunol 2002, 20:197-216. This is a recent review of innate immunity.
9. Banchereau J, Steinman RM: Dendritic cells and the control of immunity. Nature 1998, 392:245-252.
10. Banchereau J, Briere F, Caux C, et al.: Immunobiology of dendritic cells. Ann Rev Immunol 2000, 18:767-811.
11. Lanzavecchia A, Sallusto F: Regulation of T cell immunity by dendritic cells. Cell 2001, 106:263-266.
12. Guermonprez P, Valladeau J, Zitvogel L, et al.: Antigen presentation and T cell stimulation by dendritic cells. Annu Rev Immunol 2002, 20:621-667. This is a recent review of DC biology
13. Zitvogel L: Dendritic and natural killer cells cooperate in the control/switch of innate immunity. J Exp Med 2002, 195:F9-F14.
14. Moretta A: Natural killer cells and dendritic cells: rendezvous in abused tissues. Nat Rev Immunol 2002, 2:957-964.
15. Stober D, Jomantaite I, Schirmbeck R, et al.: NKT cells provide help for dendritic cell-dependent priming of MHC class I-restricted CDS(+) T cells in vivo. J Immunol 2003, 170:2540-2548.
16. Fujii S, Shimizu K, Steinman RM, et al.: Detection and activation of human Valpha24+ natural killer T cells using alpha-galactosyl ceramide-pulsed dendritic cells. J Immunol Methods 2003, 272:147-159.
17. Kadowaki N, Antonenko S, Ho S, et al.: Distinct cytokine profiles of neonatal natural killer T cells after expansion with subsets of dendritic cells. J Exp Med 2001, 193:1221-1226.
18. Dubois B, Bridon JM, Fayette J, et al.: Dendritic cells directly modulate B cell growth and differentiation. J Leukoc Biol 1999, 66:224-230.
19. Caux C, Massacrier C, Vanbervliet B, et al.: CD34+ hematopoietic progenitors from human cord blood differentiate along two independent dendritic cell pathways in response to granulocyte-macrophage colony-stimulating factor plus tumor necrosis factor alpha: II. Functional analysis. Blood 1997, 90:1458-1470.
20. Shortman K, Liu YJ: Mouse and human dendritic cell subtypes. Nat Rev Immunol 2002, 2:151-161.
21. Siegal FP, Kadowaki N, Shodell M, et al.: The nature of the principal type 1 interferon-producing cells in human blood [in-process citation]. Science 1999, 284:1835-1837.
22. Cella M, Jarrossay D, Facchetti F, et al.: Plasmacytoid monocytes migrate to inflamed lymph nodes and produce high levels of type I IFN. Nat Med 1999, 1:305-310.
23. Svensson H, Cederblad B, Lindahl M, et al.: Stimulation of natural interferon-alpha/beta-producing cells by Staphylococcus aureus. J Interferon Cytokine Res 1996, 16:7-16.
24. Cella M, Facchetti F, Lanzavecchia A, et al.: Plasmacytoid dendritic cells activated by influenza virus and CD40 ligand drive a potent Th1 polarization. Nat Immunol 2000, 1:305-310.
25. Rissoan MC, Soumelis V, Kadowaki N, et al.: Reciprocal control of T helper cell and dendritic cell differentiation. Science 1999, 283:1183-1186.
26. Gilliet M, Liu YJ: Generation of human CD8 T regulatory cells by CD40 ligand-activated plasmacytoid dendritic cells. J Exp Med 2002, 195:695-704.
27. Kadowaki N, Antonenko S, Lau JY, et al.: Natural interferon alpha/beta-producing cells link innate and adaptive immunity. J Exp Med 2000, 192:219-226.
28. Blanco P, Palucka AK, Gill M, et al.: Induction of dendritic cell differentiation by IFN-alpha in systemic lupus erythematosus. Science 2001, 294:1540-1543.
29. Paquette RL, Hsu NC, Kiertscher SM, et al.: Interferon-alpha and granulocyte-macrophage colony-stimulating factor differentiate peripheral blood monocytes into potent antigen-presenting cells. J Leukoc Biol 1998, 64:358-367.
30. Santini SM, Lapenta C, Logozzi M, et al.: Type I interferon as a powerful adjuvant for monocyte-derived dendritic cell development and activity in vitro and in Hu-PBL-SCID mice. J Exp Med 2000, 191:1777-1788.
31. Luft T, Pang KC, Thomas E, et al.: Type I IFNs enhance the terminal differentiation of dendritic cells. J Immunol 1998, 161:1947-1953.
32. Taniguchi T, Ogasawara K, Takaoka A, et al.: IRF family of transcription factors as regulators of host defense. Annu Rev Immunol 2001, 19:623-655.
33. Cederblad B, Blomberg S, Vallin H, et al.: Patients with systemic lupus erythematosus have reduced numbers of circulating natural interferon-alpha-producing cells. J Autoimmun 1998, 11:465-470.
34. Gill MA, Blanco P, Arce E, et al.: Blood dendritic cells and DC-poietins in systemic lupus erythematosus. Hum Immunol 2002, 63:1172-1180.
35. Farkas L, Beiske K, Lund-Johansen F, et al.: Plasmacytoid dendritic cells (natural interferon- alpha/beta-producing cells) accumulate in cutaneous lupus erythematosus lesions. Am J Pathol 2001, 159:237-243.
36. Blomberg S, Eloranta ML, Cederblad B, et al.: Presence of cutaneous interferon-alpha producing cells in patients with systemic lupus erythematosus. Lupus 2001, 10:484-490.
37. Jahnsen FL, Lund-Johansen F, Dunne JF, et al.: Experimentally induced recruitment of plasmacytoid (CD123high) dendritic cells in human nasal allergy. J Immunol 2000, 165:4062-4068.
38. Krug A, Rothenfusser S, Hornung V, et al.: Identification of CpG oligonucleotide sequences with high induction of IFN-alpha/beta in plasmacytoid dendritic cells. Eur J Immunol 2001, 31:2154-2163.
39. Ronnblom L, Alm GV: The natural interferon-alpha producing cells in systemic lupus erythematosus. Hum Immunol 2002, 63:1181-1193.
40. Biron CA: Interferons alpha and beta as immune regulators - a new look. Immunity 2001, 14:661-664.
41. Wang J, Lin Q, Langston H, et al.: Resident bone marrow macrophages produce type 1 interferons that can selectively inhibit interleukin-7-driven growth of B lineage cells. Immunity 1995, 3:475-484.
42. Su DM, Wang J, Lin Q, et al.: Interferons alpha/beta inhibit IL-7-induced proliferation of CD4- CD8- CD3- CD44+ CD25+ thymocytes, but do not inhibit that of CD4- CD8- CD3- CD44- CD25- thymocytes. Immunology 1997, 90:543-549.
43. Lin Q, Dong C, Cooper MD: Impairment of T and B cell development by treatment with a type I interferon. J Exp Med 1998, 187:79-87.
44. Arce E, Jackson DG, Gill MA, et al.: Increased frequency of pre-germinal center B cells and plasma cell precursors in the blood of children with systemic lupus erythematosus. J Immunol 2001, 167:2361-2369.
45. Odendahl M, Jacobi A, Hansen A, et al.: Disturbed peripheral B lymphocyte homeostasis in systemic lupus erythematosus [in-process citation]. J Immunol 2000, 165:5970-5979.
46. Galibert L, Burdin N, de Saint-Vis B, et al.: CD40 and B cell antigen receptor dual triggering of resting B lymphocytes turns on a partial germinal center phenotype. J Exp Med 1996, 183:77-85.
47. Dubois B, Vanbervliet B, Fayette J, et al.: Dendritic cells enhance growth and differentiation of CD40-activated B lymphocytes [see comments]. J Exp Med 1997, 185:941-951.
48. Dubois B, Massacrier C, Vanbervliet B, et al.: Critical role of IL-12 in dendritic cell-induced differentiation of naive B lymphocytes. J Immunol 1998, 161:2223-2231.
49. Fayette J, Dubois B, Vandenabeele S, et al.: Human dendritic cells skew isotype switching of CD40-activated naive B cells towards IgA1 and IgA2. J Exp Med 1997, 185:1909-1918.
50. Litinskiy MB, Nardelli B, Hilbert DM, et al.: DCs induce CD40-independent immunoglobulin class switching through BLyS and APRIL. Nat Immunol 2002, 3:822-829. Dendritic cells activate B cells through B lymphocyte stimulator (BLyS) and TNF-and APOL-related leukocyte expressed ligand-2 (APRIL).
51. Schneider P, MacKay F, Steiner V, et al.: BAFF, a novel ligand of the tumor necrosis factor family, stimulates B cell growth. J Exp Med 1999, 189:1747-1756.
52. Batten M, Groom J, Cachero TG, et al.: BAFF mediates survival of peripheral immature B lymphocytes. J Exp Med 2000, 192:1453-1466.
53. Gross JA, Johnston J, Mudri S, et al.: TACI and BCMA are receptors for a TNF homologue implicated in B-cell autoimmune disease [see comments]. Nature 2000, 404:995-999.
54. Balazs M, Martin F, Zhou T, et al.: Blood dendritic cells interact with splenic marginal zone B cells to initiate T-independent immune responses. Immunity 2002, 17:341.
55. MacLennan I, Vinuesa C: Dendritic Cells, BAFF, and APRIL. Innate players in adaptive antibody responses. Immunity 2002, 17:235.
56. Mackay F, Woodcock SA, Lawton P, et al.: Mice transgenic for BAFF develop lymphocytic disorders along with autoimmune manifestations. J Exp Med 1999, 190:1697-1710.
57. Bennett L, Palucka AK, Arce E, et al.: Interferon and granulopoiesis signatures in systemic lupus erythematosus blood. J Exp Med 2003, 197:711-723. This article demonstrates the use of microarray technology to analyze pediatric SLE PBMCs, allowing the demonstration of IFN and granulopoiesis signatures.
58. Baechler EC, Batliwalla FM, Karypis G, et al.: Interferon-inducible gene expression signature in peripheral blood cells of patients with severe lupus. Proc Natl Acad Sci U S A 2003, 100:2610-2615. This article demonstrates the use of microarray technology to analyze adult SLE PBMCs, allowing the demonstration of an IFN signature.
59. Winoto A, Littman DR: Nuclear hormone receptors in T lymphocytes. Cell 2002, 109(suppl):S57-S66.
60. Hooks JJ, Moutsopoulos HM, Geis SA, et al.: Immune interferon in the circulation of patients with autoimmune disease. N Engl J Med 1979, 301:5-8.
61. Kim T, Kanayama Y, Negoro N, et al.: Serum levels of interferons in patients with systemic lupus erythematosus. Clin Exp Immunol 1987, 70:562-569.
62. Preble OT, Black RJ, Friedman RM, et al.: Systemic lupus erythematosus: presence in human serum of an unusual acid-labile leukocyte interferon. Science 1982, 216:429-431.
63. Preble OT, Rothko K, Klippel JH, et al.: Interferon-induced 2′-5′ adenylate synthetase in vivo and interferon production in vitro by lymphocytes from systemic lupus erythematosus patients with and without circulating interferon. J Exp Med 1983, 157:2140-2146.
64. von Wussow P, Jakschies D, Hochkeppel H, et al.: MX homologous protein in mononuclear cells from patients with systemic lupus erythematosus. Arthritis Rheum 1989, 32:914-918.
65. Wakeland EK, Liu K, Graham RR, et al.: Delineating the genetic basis of systemic lupus erythematosus. Immunity 2001, 15:397-408.
66. James JA, Harley JB, Scofield RH: Role of viruses in systemic lupus erythematosus and Sjogren syndrome. Curr Opin Rheumatol 2001, 13:370-376.
67. Fukuda A, Kobayashi H, Teramura K, et al.: Effects of interferon-alpha on peripheral neutrophil counts and serum granulocyte colony-stimulating factor levels in chronic hepatitis C patients. Cytokines Cell Mol Ther 2000, 6:149-154.
68. Scapini P, Nardelli B, Nadali G, et al.: G-CSF-stimulated neutrophils are a prominent source of functional BLyS. J Exp Med 2003, 197:297-302.
69. Ehrenstein MR, McSweeney E, Swane M, et al.: Appearance of anti-DNA antibodies in patients treated with interferon-alpha. Arthritis Rheum 1993, 36:279-280.
70. Okanoue T, Sakamoto S, Itoh Y, et al.: Side effects of high-dose interferon therapy for chronic hepatitis C. J Hepatol 1996, 25:283-291.
71. Ronnblom LE, Alm GV, Oberg KE: Autoimmunity after alpha-interferon therapy for malignant carcinoid tumors [see comments]. Ann Intern Med 1991, 115:178-183.
72. Kalkner KM, Ronnblom L, Karlsson Parra AK, et al.: Antibodies against double-stranded DNA and development of polymyositis during treatment with interferon. QJM 1998, 91:393-399.
73. Schilling PJ, Kurzrock R, Kantarjian H, et al.: Development of systemic lupus erythematosus after interferon therapy for chronic myelogenous leukemia. Cancer 1991, 68:1536-1537.
74. Sergiescu D, Cerutti I, Efthymiou E, et al.: Adverse effects of interferon treatment on the life span of NZB mice. Biomedicine 1979, 31:48-51.
75. Heremans H, Billiau A, Colombatti A, et al.: Interferon treatment of NZB mice: accelerated progression of autoimmune disease. Infect Immun 1978, 21:925-930.
76. Santiago-Raber ML, Baccala R, Haraldsson KM, et al.: Type-I interferon receptor deficiency reduces lupus-like disease in NZB mice. J Exp Med 2003, 197:777-788.
77. Braun D, Geraldes P, Demengeot J: Type I interferon controls the onset and severity of autoimmune manifestations in lpr mice. J Autoimmun 2003, 20:15-25.
78. Rozzo SJ, Allard JD, Choubey D, et al.: Evidence for an interferon-inducible gene, lfi202, in the susceptibility to systemic lupus. Immunity 2001, 15:435-443.
79. Feldmann M, Maini RN: Anti-TNF alpha therapy of rheumatoid arthritis: what have we learned? Annu Rev Immunol 2001, 19:163-196.